Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Immunome, Inc.

IMNM ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: BUY

Last Close

$17.91

▼ -8.27%

Market Cap $2.11B · Vol 635.07K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$2.11B

Mid Cap

Div Yield

N/A

EPS Growth

+1.08%

YoY

RSI (14)

58.85

Momentum

Beta

2.63

vs Market

52W High

$30.05

40.42% below

52W Low

$14.65

22.22% above

Volume

635.07K

Avg 521.67K

P/B

3.83

Price-to-book

ROE

-52.09%

Return on equity

Free Float

93.58%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Immunome, Inc. (IMNM) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does IMNM pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-2.10%

-15.42%

-29.84%

-22.52%

YTD

-16.64%

+16.64%

+103.93%

-13.21%

Financials & Valuation

TTM · Annual

Total Revenue	$6.94M
Net Income	$-212,394,000.00
Revenue Growth (YoY)	-100.00%
Gross Margin	100.00%
Operating Margin	-3,084.76%
Net Profit Margin	-3,059.99%
ROE	-52.09%
ROA · ROIC	-46.00% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	270.32
P/B	3.83
P/FCF	N/A
EPS Growth	+1.08%
Outstanding Shares	118.00M

Technical Indicators

50-Day SMA	$21.69
200-Day SMA	$22.41
RSI (14)	58.85
Beta	2.63
52-Week High	$30.05
52-Week Low	$14.65

Volume Today	635.07K
Avg Daily Volume (30D)	521.67K
Relative Volume	1.22x
Volatility (10D)	68.66
Volatility (30D)	61.80
Free Float	93.58%

Analyst Consensus

BUY

Current Price $17.91

Mean Target $34.93

52W Low$14.65 52W High$30.05

Current

Target

$14.65 $30.05

Current Analyst target

+95.08% upside potential · 16 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00BR94298

ISINUS45257U1088

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. +3.34% ARGX.BR argenx SE +0.07% ARGX argenx SE -3.93% GMAB.CO Genmab A/S +1.59% GMAB Genmab A/S -4.32%

Company Profile

Immunome, Inc. is a clinical-stage targeted oncology company, which is focused on developing first-in-class and targeted therapies designed to improve outcomes for cancer patients. The Company is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The Company's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.